Lilly sees its own credibility problem, and the industry's, as a major financial challenge--compromising approvals, marketing claims and pricing. It also contends its solution, providing far more information about its products through its marketing and R&D organizations, provides a solution for the industry as a whole. But as it's been rolled out so far, the strategy will disproportionately benefit Lilly.
By Roger Longman
January 27, 2005 was a good day for Eli Lilly & Co. Almost a month after the British Medical...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
The culmination of the MedTech Innovator APAC awards program 2025 comes later this month when the top prizes are handed out at the grand final in Singapore. But all cohort companies benefit from the competition’s mentoring process, says awards organizer Fredrik Nyberg.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The billion-dollar startup has doubled headcount, released massive datasets and is advancing therapeutics, but the hard part lies ahead.
Essential Pharma CEO Emma Johnson discusses the company’s strategic priorities and plans for growth as it expands its portfolio in rare diseases.
Chinese medtechs are expanding rapidly worldwide, but gaining market access within China itself – poised to become the world’s largest medtech market – is proving to be a very different challenge.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The billion-dollar startup has doubled headcount, released massive datasets and is advancing therapeutics, but the hard part lies ahead.
